RESEARCH · NAD+ · MEMBRANE TRANSPORT
Can NAD+ Enter Cells? Ectoenzymes, the Slc12a8 Debate and the Mitochondrial Transporter SLC25A51
Most NAD+ research materials, including PurixLab’s NAD+ 500mg, are the intact dinucleotide. A recurring question in the literature is deceptively simple: can an NAD+ molecule outside a cell actually get into that cell, and into its mitochondria? Our earlier articles cover coenzyme biology, CD38 and PARP consumption and NR versus NMN human trials. This one focuses on membrane transport: ectoenzyme conversion, the disputed Slc12a8 NMN transporter, and the mitochondrial carrier SLC25A51. NAD+ 500mg is a research material for laboratory research use only; none of the studies below is a claim about any product.
The default route: cleave outside, rebuild inside
A detailed study of human cells mapped how extracellular precursors enter: only nicotinamide, nicotinic acid and their corresponding nucleosides readily cross the membrane, while nucleotides such as NAD+ and NMN undergo extracellular degradation to those permeable precursors before uptake [1]. In HEK293 cultures, mono- and dinucleotides were degraded to nucleosides and then to bases, degradation also occurred in serum-containing medium without cells, and pharmacological blockade showed that extracellular cleavage of NAD+ and NMN to nicotinamide riboside (NR) is a prerequisite for maintaining intracellular NAD [2]. The nucleosides themselves cross through equilibrative nucleoside transporters ENT1, ENT2 and ENT4 [3], and nicotinamide riboside kinase 1 (NRK1) is rate-limiting for turning NR and NMN into NAD+ once inside, with stable-isotope data showing NMN is metabolised extracellularly to NR before uptake [4].
Ectoenzymes: CD38 and CD73 as gatekeepers
Because the nucleotides are cleaved first, the ectoenzymes that do the cleaving matter. CD73 can act as a source of extracellular precursors for sustained NAD+ biosynthesis: by specifically silencing or overexpressing CD38 and CD73, one group showed that endogenous CD73 enables, whereas CD38 impairs, the conversion of extracellular NMN to NR as a precursor for intracellular NAD+ [5]. The picture is not unanimous: another study found that extracellular NAD+ and NMN restored intracellular NAD+ and PARP-dependent DNA repair independently of CD73, and that recombinant CD73 only poorly processed NMN and not NAD+ [6]. So the exact ectoenzyme cascade is cell-type dependent and still contested.
The Slc12a8 claim and the debate around it
In 2019 a group reported that the Slc12a8 gene encodes a specific, sodium-dependent NMN transporter that moves intact NMN into cells, is highly expressed in the mouse small intestine, and regulates intestinal NAD+ [7]. The claim was quickly challenged: a formal comment argued there was an absence of evidence that Slc12a8 encodes an NMN transporter [8], and the original authors published a reply defending their data [9]. Later work continued to use Slc12a8 as an NMN transporter in specific tissues, for example in the lateral hypothalamus linked to energy metabolism and skeletal-muscle function during aging [10], and reviews fold it into a broader NMN/eNAMPT regulatory model [11]. The dispute matters because a direct, intact-NMN transporter would partly bypass the cleave-then-rebuild route; whether it operates widely in human cells is unresolved.
Complicating any oral-precursor comparison, mouse tracing shows that most orally administered NMN and NR are not absorbed intact: they undergo gut-microbiota-mediated deamidation to nicotinic acid, which is then used via enterohepatic circulation [12]. Other studies similarly document host-microbiome deamidation of NMN and a bacterial deamidated pathway contributing to host NAD [13,14]. These are precursor studies in animals, not statements about intact NAD+.
Does intact NAD+ ever enter cells?
Some evidence points to a channel-based route independent of cleavage. In astrocytes, extracellular NAD+ (but not nicotinamide or adenosine) restored NAD+ levels and prevented PARP-mediated cell death, and the effect was blocked by connexin-hemichannel inhibitors but not by P2X7 or pannexin blockers, suggesting intact NAD+ enters through connexin hemichannels [15]. Connexin-43 hemichannels have independently been shown to transport NAD+ out of cells and cyclic ADP-ribose back in [16]. These are specific cell types under specific conditions, so they qualify rather than overturn the general cleave-first model.
Into mitochondria: SLC25A51
The largest subcellular NAD pool is mitochondrial, and how it is filled was long uncertain. Early tracing with doubly labelled nicotinamide riboside argued that mammalian mitochondria take up intact NAD(H) [17]. In 2020 two groups independently identified SLC25A51 (also called MCART1) as a mammalian mitochondrial NAD+ transporter: loss of SLC25A51 decreased mitochondrial but not whole-cell NAD+ and blocked NAD+ uptake into isolated mitochondria, while overexpression increased it [18], and a parallel study found MCART1/SLC25A51 coessential with electron-transport-chain components and required for mitochondrial NAD transport [19]. A 2025 study showed the mitochondrial membrane potential works with charged residues in the carrier to import this anionic molecule against its gradient [20]. This partly reconciles the older debate: intact NAD+ does reach the matrix, but through a dedicated protein carrier, not free diffusion.
What this means for a laboratory reader
- Extracellular is not intracellular. Adding NAD+ to a medium does not guarantee intact NAD+ inside cells; much is cleaved first [1,2].
- The route depends on the cell. Ectoenzyme balance (CD38, CD73), ENT transporters and NRK1 all shape the outcome, and findings conflict [5,6,3].
- Slc12a8 is unsettled. A direct NMN transporter was reported and disputed, and is not established in human cells [7,8,9].
- Mitochondrial entry is carrier-mediated. SLC25A51 imports intact NAD+ driven by membrane potential [18,19,20].
- Material identity still matters. Published biology says nothing about a specific vial; NAD+ is a dinucleotide, not a peptide, so follow the label and your laboratory’s procedures.
NAD+ 500mg at PurixLab
NAD+ 500mg: a labelled lyophilized research vial with 500mg per vial, C$109 per vial (CAD, before tax), supplied for laboratory research only. NAD+ is a coenzyme, not a peptide. Batch documentation is available on request. Product page: purixlab.com/product/nad-500mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Nikiforov A, Dölle C, Niere M, et al. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J Biol Chem. 2011;286(24):21767-78. PubMed 21504897 · PMC3122232 · doi:10.1074/jbc.M110.213298
- Kulikova V, Shabalin K, Nerinovski K, et al. Degradation of Extracellular NAD+ Intermediates in Cultures of Human HEK293 Cells. Metabolites. 2019;9(12):293. PubMed 31795381 · PMC6950141 · doi:10.3390/metabo9120293
- Kropotov A, Kulikova V, Nerinovski K, et al. Equilibrative Nucleoside Transporters Mediate the Import of Nicotinamide Riboside and Nicotinic Acid Riboside into Human Cells. Int J Mol Sci. 2021;22(3):1391. PubMed 33573263 · PMC7866510 · doi:10.3390/ijms22031391
- Ratajczak J, Joffraud M, Trammell SA, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:13103. PubMed 27725675 · PMC5476803 · doi:10.1038/ncomms13103
- Grozio A, Sociali G, Sturla L, et al. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J Biol Chem. 2013;288(36):25938-25949. PubMed 23880765 · PMC3764798 · doi:10.1074/jbc.M113.470435
- Wilk A, Hayat F, Cunningham R, et al. Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity. Sci Rep. 2020;10(1):651. PubMed 31959836 · PMC6971268 · doi:10.1038/s41598-020-57506-9
- Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(1):47-57. PubMed 31131364 · PMC6530925 · doi:10.1038/s42255-018-0009-4
- Schmidt MS, Brenner C. Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(7):660-661. PubMed 32694648 · doi:10.1038/s42255-019-0085-0
- Grozio A, Mills K, Yoshino J, et al. Reply to: Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter. Nat Metab. 2019;1(7):662-665. PubMed 32694650 · doi:10.1038/s42255-019-0086-z
- Ito N, Takatsu A, Ito H, et al. Slc12a8 in the lateral hypothalamus maintains energy metabolism and skeletal muscle functions during aging. Cell Rep. 2022;40(4):111131. PubMed 35905718 · doi:10.1016/j.celrep.2022.111131
- Imai SI. NAD World 3.0: the importance of the NMN transporter and eNAMPT in mammalian aging and longevity control. NPJ Aging. 2025;11(1):4. PubMed 39870672 · PMC11772665 · doi:10.1038/s41514-025-00192-6
- Yaku K, Palikhe S, Iqbal T, et al. Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation. Sci Adv. 2025;11(12):eadr1538. PubMed 40117359 · PMC11927621 · doi:10.1126/sciadv.adr1538
- Kim LJ, Chalmers TJ, Madawala R, et al. Host-microbiome interactions in nicotinamide mononucleotide (NMN) deamidation. FEBS Lett. 2023;597(17):2196-2220. PubMed 37463842 · doi:10.1002/1873-3468.14698
- Shats I, Williams JG, Liu J, et al. Bacteria Boost Mammalian Host NAD Metabolism by Engaging the Deamidated Biosynthesis Pathway. Cell Metab. 2020;31(3):564-579.e7. PubMed 32130883 · PMC7194078 · doi:10.1016/j.cmet.2020.02.001
- Okuda H, Nishida K, Higashi Y, et al. NAD(+) influx through connexin hemichannels prevents poly(ADP-ribose) polymerase-mediated astrocyte death. Life Sci. 2013;92(13):808-14. PubMed 23454167 · doi:10.1016/j.lfs.2013.02.010
- Song EK, Rah SY, Lee YR, et al. Connexin-43 hemichannels mediate cyclic ADP-ribose generation and its Ca2+-mobilizing activity by NAD+/cyclic ADP-ribose transport. J Biol Chem. 2011;286(52):44480-90. PubMed 22033928 · PMC3247979 · doi:10.1074/jbc.M111.307645
- Davila A, Liu L, Chellappa K, et al. Nicotinamide adenine dinucleotide is transported into mammalian mitochondria. Elife. 2018;7:e33246. PubMed 29893687 · PMC6013257 · doi:10.7554/eLife.33246
- Luongo TS, Eller JM, Lu MJ, et al. SLC25A51 is a mammalian mitochondrial NAD+ transporter. Nature. 2020;588(7836):174-179. PubMed 32906142 · PMC7718333 · doi:10.1038/s41586-020-2741-7
- Kory N, Uit de Bos J, van der Rijt S, et al. MCART1/SLC25A51 is required for mitochondrial NAD transport. Sci Adv. 2020;6(43):eabe5310. PubMed 33087354 · PMC7577609 · doi:10.1126/sciadv.abe5310
- Goyal S, Lyons SN, Cambronne XA. Mitochondrial NAD+ gradient sustained by membrane potential and transport. Sci Adv. 2025;11(47):eaea7460. PubMed 41270176 · PMC12637306 · doi:10.1126/sciadv.aea7460